Menu

About RedHill

RedHill Biopharma Ltd. (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

The Company’s current product pipeline includes:

RHB-104 - An oral combination therapy with positive top-line results from a first Phase 3 study for Crohn's disease.

RHB-204 - An oral combination therapy with a planned pivotal Phase 3 study for nontuberculous mycobacteria (NTM) infections.

RHB-102 (Bekinda®) - A once-daily oral pill formulation of ondansetron with positive results from a Phase 3 study in acute gastroenteritis and gastritis and positive results from a Phase 2 study in IBS-D.

ABC294640 (OpaganibYeliva®) - an orally-administered, first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma.

RHB-106 - An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd. (now Bausch Health).

RHB-107  - A Phase 2-stage, orally-administered, first-in-class, serine protease inhibitor, targeting gastrointestinal and other solid tumor cancers. 
 

RedHill commercializes and promotes three gastrointestinal products in the U.S. and plans to launch two additional approved prescription drugs:

Talicia® (omeprazole, amoxicillin and rifabutin)

Aemcolo® (rifamycin)

Donnatal® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide)

EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI)

Mytesi® (crofelemer 125 mg delayed-release tablets)